Durga Bestha1, Layla Soliman1, Kelly Blankenship2, James Rachal3. 1. Department of Psychiatry, Atrium Health, Charlotte, NC, USA. 2. Michigan State University, East Lansing, MI, USA. 3. Department of Psychiatry, Atrium Health, Charlotte, NC, USA. James.rachal@carolinashealthcare.org.
Abstract
PURPOSE OF REVIEW: We review the published literature over the last 24 months in the treatment of PTSD for our military men and women. We examined the updated clinical practice guidelines published in June 2017 by the Veteran's administration and Department of Defense and contrasted the guidelines with the most recent literature. We also discuss new directions in PTSD research. RECENT FINDINGS: Psychotherapy remains one of the most effective treatments for PTSD; unfortunately, few participants remain in treatment to completion. Many of the emerging therapies target NMDA receptor antagonists, cannabinoid receptor modulators, glucocorticoid receptor agonists, non-SSRI antidepressants, and opioid receptor agonists. The newer therapies fall into the drug classes of anti-hypertensives, glutamate modulators, oxytocin, and medication targeting insomnia/hyperarousal. PTSD symptoms are often chronic in our veteran population. While current treatments are helpful, there are often significant residual symptoms. We reviewed the most recent improvements in treatment and discuss therapies that are in the research phase.
PURPOSE OF REVIEW: We review the published literature over the last 24 months in the treatment of PTSD for our military men and women. We examined the updated clinical practice guidelines published in June 2017 by the Veteran's administration and Department of Defense and contrasted the guidelines with the most recent literature. We also discuss new directions in PTSD research. RECENT FINDINGS: Psychotherapy remains one of the most effective treatments for PTSD; unfortunately, few participants remain in treatment to completion. Many of the emerging therapies target NMDA receptor antagonists, cannabinoid receptor modulators, glucocorticoid receptor agonists, non-SSRI antidepressants, and opioid receptor agonists. The newer therapies fall into the drug classes of anti-hypertensives, glutamate modulators, oxytocin, and medication targeting insomnia/hyperarousal. PTSD symptoms are often chronic in our veteran population. While current treatments are helpful, there are often significant residual symptoms. We reviewed the most recent improvements in treatment and discuss therapies that are in the research phase.
Authors: Mirjam van Zuiden; Jessie L Frijling; Laura Nawijn; Saskia B J Koch; J Carel Goslings; Jan S Luitse; Tessa H Biesheuvel; Adriaan Honig; Dick J Veltman; Miranda Olff Journal: Biol Psychiatry Date: 2016-12-08 Impact factor: 13.382
Authors: Sudie E Back; Jenna L McCauley; Kristina J Korte; Daniel F Gros; Virginia Leavitt; Kevin M Gray; Mark B Hamner; Stacia M DeSantis; Robert Malcolm; Kathleen T Brady; Peter W Kalivas Journal: J Clin Psychiatry Date: 2016-11 Impact factor: 4.384
Authors: Ann M Rasmusson; Christine E Marx; Sonia Jain; Gail M Farfel; Julia Tsai; Xiaoying Sun; Thomas D Geracioti; Mark B Hamner; James Lohr; Richard Rosse; Lanier Summerall; Jennifer C Naylor; Cristine Cusin; Ariel J Lang; Rema Raman; Murray B Stein Journal: Psychopharmacology (Berl) Date: 2017-07-01 Impact factor: 4.530
Authors: John H Krystal; Chadi G Abdallah; Lynette A Averill; Benjamin Kelmendi; Ilan Harpaz-Rotem; Gerard Sanacora; Steven M Southwick; Ronald S Duman Journal: Curr Psychiatry Rep Date: 2017-08-26 Impact factor: 5.285
Authors: Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney Journal: JAMA Psychiatry Date: 2014-06 Impact factor: 21.596